Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

ABSTRACT: Adoptive cell therapy with tumor-targeted T cells is a promising approach to cancer therapy. Enhanced clinical outcome using this approach requires conditioning regimens with total body irradiation, lymphodepleting chemotherapy, and/or additional cytokine support. However, the need for prior conditioning precludes optimal application of this approach to a significant number of cancer patients intolerant to these regimens. Herein, we present preclinical studies demonstrating that treatment with CD19-specific, chimeric antigen receptor (CAR)-modified T cells that are further modified to constitutively secrete IL-12 are able to safely eradicate established disease in the absence of prior conditioning. We demonstrate in a novel syngeneic tumor model that tumor elimination requires both CD4(+)

SUBMITTER: Pegram HJ 

PROVIDER: S-EPMC3359735 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature